STRATA Skin Sciences Q2 revenue $8.3M, net loss $3.1M; FY guidance cut to $35-38M

STRATA Skin Sciences, Inc.

2023-Q2 EPS reported -$0.17 revenue$15,817,000

Q2 revenue $8.3M vs $9.1M YoY; equipment revenue down to $2.8M from $3.5M due to $1.5M one-time China sale last year.
Net loss $3.1M ($0.09 loss per share) vs $1.9M ($0.05 loss) YoY; adjusted EBITDA loss of $95K vs positive $207K.
FY 2023 guidance revised to $35-38M from prior; cites slowdown in capex and macro factors impacting equipment sales.
Secured up to $12M financing with MidCap Financial; cash balance $10.4M; includes refinancing and $7M new tranche.
73 TheraClear X devices placed; initiated acne clinical study; JCAD publication released.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STRATA Skin Sciences, Inc. reported second quarter ended June 30, 2023 results: revenue $8.3 million, net income $3.1 million, or a loss of $0.09 per basic and diluted common share, EPS $0.09 loss per basic and diluted common share. Guidance lowered.

Period: second quarter ended June 30, 2023
Revenue: $8.3 million
Net income: $3.1 million, or a loss of $0.09 per basic and diluted common share
EPS: $0.09 loss per basic and diluted common share
Guidance: lowered
Result: reported results

Exact text from the filing

today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights: ● Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022. ● Secured up to an additional $12 million financing with MidCap Financial. ● Placed 73 TheraClear ® X devices as of June

View on SEC.gov

Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-038802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.